ID   CCRF-HSB-2
AC   CVCL_1859
AS   CVCL_5938
SY   CCRF HSB-2; CCRF-HSB2; HSB-2; HSB.2; HSB2; H-SB2; SB-2; HSB; H.S.B.; GM04155
DR   BTO; BTO:0005370
DR   CLO; CLO_0002335
DR   CLO; CLO_0004258
DR   CLO; CLO_0016177
DR   CLO; CLO_0050971
DR   EFO; EFO_0022508
DR   CLDB; cl678
DR   ATCC; CCL-120.1
DR   BEI_Resources; ARP-497
DR   BioSample; SAMN03472334
DR   BioSample; SAMN03472701
DR   BioSample; SAMN03473542
DR   cancercelllines; CVCL_1859
DR   Cell_Model_Passport; SIDM01558
DR   ChEMBL-Cells; CHEMBL3307642
DR   ChEMBL-Targets; CHEMBL614541
DR   CLS; 300214
DR   Coriell; GM04155
DR   Cosmic; 683532
DR   Cosmic; 801729
DR   Cosmic; 850195
DR   Cosmic; 913416
DR   Cosmic; 922679
DR   Cosmic; 932768
DR   Cosmic; 996307
DR   Cosmic; 998723
DR   Cosmic; 1037688
DR   Cosmic; 1115591
DR   Cosmic; 1175128
DR   Cosmic; 1226856
DR   Cosmic; 1281369
DR   Cosmic; 1330497
DR   Cosmic; 1524797
DR   Cosmic; 1641390
DR   Cosmic; 1760523
DR   Cosmic; 2165712
DR   Cosmic; 2361365
DR   Cosmic; 2458762
DR   Cosmic; 2462861
DR   Cosmic; 2602915
DR   Cosmic; 2649236
DR   DSMZ; ACC-435
DR   DSMZCellDive; ACC-435
DR   ECACC; 85112801
DR   GEO; GSM5137752
DR   IARC_TP53; 21649
DR   IZSLER; BS TCL 185
DR   JCRB; JCRB0031
DR   KCLB; 10120.1
DR   LINCS_LDP; LCL-1914
DR   NCBI_Iran; C530
DR   PRIDE; PXD023662
DR   PubChem_Cell_line; CVCL_1859
DR   RCB; RCB0016
DR   Wikidata; Q54809037
RX   CelloPub=CLPUB00447;
RX   DOI=10.1007/BF02618370;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=62390;
RX   PubMed=168255;
RX   PubMed=1086134;
RX   PubMed=2140233;
RX   PubMed=2144611;
RX   PubMed=2255914;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3495441;
RX   PubMed=3874327;
RX   PubMed=4363409;
RX   PubMed=4523807;
RX   PubMed=4991454;
RX   PubMed=6582512;
RX   PubMed=6600440;
RX   PubMed=7630190;
RX   PubMed=8316623;
RX   PubMed=8547074;
RX   PubMed=8558913;
RX   PubMed=8957066;
RX   PubMed=9787181;
RX   PubMed=9933131;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=15472075;
RX   PubMed=15901131;
RX   PubMed=17117183;
RX   PubMed=17170727;
RX   PubMed=22675565;
RX   PubMed=35354797;
CC   Problematic cell line: Partially contaminated. The stock formerly distributed by CLS under catalog number 300214 was contaminated. Compared to the STR values obtained by other distributors it differed from having: Amelogenin: X; CSF1PO: 8,12; D16S539: 9,13,14; D18S51: 9,13,14; D21S11: 28,29; D7S820: 10,14; D8S1179: 9,15; FGA: 22,23,24; Penta D: 9; Penta E: 6,13 and TH01: 8,10.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Characteristics: Established by serial transplantation into newborn Syrian hamsters.
CC   Doubling time: 40 hours (PubMed=17117183); ~25 hours (DSMZ=ACC-435); 24 hours (Note=Lot 042091) (JCRB=JCRB0031).
CC   Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=2255914).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2144611).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: CCRF-HBS-2; NCBI_Iran=C530.
CC   Discontinued: CLS; 300214; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC=CCL-120.1; DSMZ=ACC-435; ECACC=85112801; JCRB=JCRB0031; KCLB=10120.1; RCB=RCB0016
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11 (DSMZ=ACC-435)
ST   CSF1PO: 10,12 (ATCC=CCL-120.1; ECACC=85112801; JCRB=JCRB0031; KCLB=10120.1; RCB=RCB0016)
ST   D13S317: 10,12
ST   D16S539: 9,12 (DSMZ=ACC-435)
ST   D16S539: 9,13 (ATCC=CCL-120.1; ECACC=85112801; JCRB=JCRB0031; RCB=RCB0016)
ST   D18S51: 9,14
ST   D19S433: 14,20
ST   D21S11: 27,28
ST   D2S1338: 17,18
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   D8S1179: 10,15
ST   FGA: 24,25
ST   Penta D: 9,12
ST   Penta E: 8,13
ST   TH01: 9,10 (ATCC=CCL-120.1; DSMZ=ACC-435; ECACC=85112801; JCRB=JCRB0031; RCB=RCB0016)
ST   TH01: 9,9.3 (KCLB=10120.1)
ST   TPOX: 8
ST   vWA: 18,19 (ATCC=CCL-120.1; DSMZ=ACC-435; ECACC=85112801; JCRB=JCRB0031; KCLB=10120.1)
ST   vWA: 18,19,20 (RCB=RCB0016)
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1860 ! CCRF-SB
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 42
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992).
//
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=62390; DOI=10.1111/j.1365-3083.1976.tb03029.x;
RA   Yount W.J., Utsinger P.D., Hutt L.M., Buchanan P.D., Korn J.H.,
RA   Fuller C.R., Logue M., Pagano J.S.;
RT   "Subpopulations of human lymphoblastoid cell lines. Correlation with
RT   the expression of surface receptors and content of Epstein-Barr virus
RT   genome.";
RL   Scand. J. Immunol. 5:795-810(1976).
//
RX   PubMed=168255; DOI=10.4049/jimmunol.115.1.243;
RA   Hutt L.M., Huang Y.-T., Dascomb H.E., Pagano J.S.;
RT   "Enhanced destruction of lymphoid cell lines by peripheral blood
RT   leukocytes taken from patients with acute infectious mononucleosis.";
RL   J. Immunol. 115:243-248(1975).
//
RX   PubMed=1086134;
RA   Kaplan J., Peterson W.D. Jr.;
RT   "Detection of T-cell lymphoma-associated antigens on cord blood
RT   lymphocytes and phytohemagglutinin-stimulated blasts.";
RL   Cancer Res. 36:3471-3475(1976).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990; PMCID=PMC361264;
RA   Cheng J., Haas M.;
RT   "Frequent mutations in the p53 tumor suppressor gene in human leukemia
RT   T-cell lines.";
RL   Mol. Cell. Biol. 10:5502-5509(1990).
//
RX   PubMed=2255914; DOI=10.1126/science.2255914;
RA   Aplan P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L.,
RA   Kirsch I.R.;
RT   "Disruption of the human SCL locus by 'illegitimate' V-(D)-J
RT   recombinase activity.";
RL   Science 250:1426-1429(1990).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3495441; DOI=10.1002/eji.1830170503;
RA   Kanowith-Klein S., Saxon A., Uittenbogaart C.H.;
RT   "Constitutive production of B cell differentiation factor-like
RT   activity by human T and B cell lines.";
RL   Eur. J. Immunol. 17:593-598(1987).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=4363409; DOI=10.1084/jem.139.5.1070; PMCID=PMC2139653;
RA   Kaplan J., Shope T.C., Peterson W.D. Jr.;
RT   "Epstein-Barr virus-negative human malignant T-cell lines.";
RL   J. Exp. Med. 139:1070-1076(1974).
//
RX   PubMed=4523807; DOI=10.1007/BF02616012;
RA   Lazarus H., Barell E.F., Oppenheim S.O., Krishan A.;
RT   "Divergent properties of two human lymphocytic cell lines isolated
RT   from a single specimen of peripheral blood.";
RL   In Vitro 9:303-310(1974).
//
RX   PubMed=4991454; DOI=10.1016/0014-4827(79)90504-4;
RA   Adams R.A., Pothier L., Flowers A., Lazarus H., Farber S., Foley G.E.;
RT   "The question of stemlines in human acute leukemia. Comparison of
RT   cells isolated in vitro and in vivo from a patient with acute
RT   lymphoblastic leukemia.";
RL   Exp. Cell Res. 62:5-10(1970).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
//
RX   PubMed=7630190;
RA   Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W. Jr.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x; PMCID=PMC5920998;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000), 255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. 4th, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447; PMCID=PMC2360743;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   De Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463; PMCID=PMC3366948;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5; PMCID=PMC8967900;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//